Although the drugs on targeting splicing have not been fully overcome, with further studies on the pathophysiological mechanisms of SF3B1 splicing factor mutations in malignant hematologic tumors, systematic characterization and evaluation of the splicing events generated by these mutations provide highly informative insights from diagnosis to prognosis to targeted therapy.SF3B1, as a potential target for MDS treatment, will give practical aid for future clinical work. Here, SF3B1 is linked to myelodysplastic syndrome.